
AbbVie Reports Phase 3 EPCORE® DLBCL-1 Topline Results for Epcoritamab in R/R DLBCL
AbbVie Reports Phase 3 EPCORE® DLBCL-1 Topline Results for Epcoritamab in Relapsed/Refractory DLBCL AbbVie today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, compared to investigator’s choice of chemoimmunotherapy in…










